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Purpose To characterise the prevalence of pathogenic
germline mutations in BRCA1 and BRCA2 in families
with breast cancer (BC) and ovarian cancer (OC) history.
Patients and methods Data from 21 401 families
were gathered between 1996 and 2014 in a clinical
setting in the German Consortium for Hereditary Breast
and Ovarian Cancer, comprising full pedigrees with
cancer status of all individual members at the time of
first counselling, and BRCA1/2 mutation status of the
index patient.
Results The overall BRCA1/2 mutation prevalence was
24.0% (95% CI 23.4% to 24.6%). Highest mutation
frequencies were observed in families with at least two
OCs (41.9%, 95% CI 36.1% to 48.0%) and families
with at least one breast and one OC (41.6%, 95% CI
40.3% to 43.0%), followed by male BC with at least
one female BC or OC (35.8%; 95% CI 32.2% to
39.6%). In families with a single case of early BC
(<36 years), mutations were found in 13.7% (95% CI
11.9% to 15.7%). Postmenopausal unilateral or bilateral
BC did not increase the probability of mutation
detection. Occurrence of premenopausal BC and OC in
the same woman led to higher mutation frequencies
compared with the occurrence of these two cancers in
different individuals (49.0%; 95% CI 41.0% to 57.0%
vs 31.5%; 95% CI 28.0% to 35.2%).
Conclusions Our data provide guidance for healthcare
professionals and decision-makers to identify individuals
who should undergo genetic testing for hereditary breast
and ovarian cancer. Moreover, it supports informed
decision-making of counselees on the uptake of genetic
testing.
INTRODUCTION
Women with pathogenic germline mutations in the
BRCA1 and BRCA2 genes are at an increased life-
time risk for breast cancer (BC) and ovarian cancer
(OC) compared with the general population.1
Identification of mutation carriers is an important
prerequisite for targeted clinical management. The
probability of finding a deleterious germline muta-
tion in a woman affected with BC or OC depends
on her familial cancer history in terms of type,
number and ages of onset of these cancers.2–5 To
date, the decision to perform mutation testing is
mainly guided by the presence of a family cancer
history, which is indicative for a BRCA mutation
with a certain probability.6–8 Consequently, to
define appropriate clinical selection criteria, precise
knowledge on expected mutation frequencies for
individual family histories is required. Since the dis-
covery of the BRCA1 and BRCA2 genes, several
studies have analysed the relationship between
family history and BRCA mutation prevalence.9–14
In the largest study so far, Frank et al11 correlated
familial disease histories of 10 000 consecutively
enrolled individuals with mutation status, resulting
in detailed tabulations of empiric mutation
prevalences.
In 1996, the German Consortium for Hereditary
Breast and Ovarian Cancer (GC-HBOC) had estab-
lished a panel of clinical criteria for genetic testing
of individuals in a clinical setting, based on familial
BC and OC history.7 By the end of 2014, a total of
21 401 families suspected of having a deleterious
BRCA mutation according to this panel of clinical
criteria were enrolled into the central registry of
GC-HBOC. Based on this data set, we aimed to
comprehensively analyse the correlation of family
history of BC and OC with BRCA mutation fre-
quencies. We were particularly interested in the
predictive value of the number of premenopausal
versus postmenopausal BCs in the family, and the
presence of premenopausal or postmenopausal
bilateral breast cancer (bBC) versus unilateral
cancer. With this analysis, we aim to provide guid-
ance for counsellors, counselees and decision-
makers on the offer and uptake of genetic testing.
MATERIALS AND METHODS
The GC-HBOC comprises 15 university centres.
Using standardised clinical criteria (table 2),
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families with clustering or early onset of BC or OC are regis-
tered and tested for the presence of deleterious germline muta-
tions in BRCA1 and BRCA2. Comprehensive data on familial
cancer history, including a detailed pedigree, pathology reports
and results of molecular testing, are documented in a central
database using standardised electronic case report forms.
A total number of 21 401 families, who were registered from
1996 until 2014, were included in the present analysis. All fam-
ilies fulfilled the clinical inclusion criteria shown in table 2.
Families who were ascertained through a known pathogenic
mutation rather than by clinical criteria were not included. If
possible, the family member with the most severe phenotype
(defined as bBC, BC and OC, or earliest age of onset) was
chosen as the index patient and was searched for BRCA1 and
BRCA2 mutations. In case that no DNA from an affected family
member could be obtained, mutation analysis was performed in
unaffected individuals. BC included ductal carcinoma in situ.
OC included cancers of the fallopian tube and primary periton-
eal cancers irrespective of histopathological subtype and
grading. BC cases with an age of onset of 50 years or earlier are
hereafter referred to as premenopausal BC (BC50−). BC at the
age from 51 years onwards are referred to as postmenopausal
BC (BC51+). For bBC, the age of onset of the first cancer was
considered. The present study did not include families with
single cases of OC or single cases of male breast cancer (mBC)
since these families were not part of the clinical inclusion
criteria.
Mutation analysis
Mutation analysis was performed using direct sequencing or a
pre-screening step followed by direct sequencing of suspect frag-
ments. Pre-screening methods comprised mainly denaturing
high-performance liquid chromatography and high-resolution
melting.15 16 Before the year 1999, single-strand conformation
polymorphism and protein truncation test were used. If no dele-
terious sequence alterations were found in these steps, an add-
itional screening for large genomic alterations was performed
using multiplex ligation-dependent probe amplification. In the
present study, 88.4% of all BRCA1/2-negative index patients
were searched for large genomic alterations. Mutations were
classified according to the International Agency for Research on
Cancer (IARC) system and considered pathogenic or likely
pathogenic (class 4 or 5) based on literature evidence, multifac-
torial likelihood and functional analyses of the ENIGMA con-
sortium that comprises genetic data of the GC-HBOC
database.17–19
Statistical analysis
IBM SPSS 22 was used for statistical analysis. The 95% CIs
for mutation frequencies were calculated using Wilson’s score
Table 1 Family characteristics
Total BRCA1 BRCA2 Negative
Families, no 21 401 3398 1766 16 265
Members
Total number 617 578 99 708 52 861 466 013
Median per family 25 26 26 25
Members with cancer, no
uBC50− 26 236 4996 2519 18 770
uBC51+ 24 452 2789 2033 19 655
bBC50− 4132 1304 427 2414
bBC51+ 1896 239 168 1492
OC 7250 2650 730 3897
BC and OC 1917 805 202 916
Male BC 671 62 193 420
Age of onset (mean)*
BC 49.0 44.4 47.5 50.2
OC 51.5 49.8 55.6 51.9
Male BC 58.0 56.9 60.4 57.0
*Mean ages of onset for BC and OC were significantly different in all pairwise group
comparisons (p<0.001). For male BC, mean age of onset was significantly different
between BRCA2-positive and BRCA1/2-negative families (p=0.006).
bBC, bilateral breast cancer; BC, breast cancer; OC, ovarian cancer.
Table 2 Familial breast and ovarian cancer histories used as inclusion criteria for BRCA1/2 mutation testing in German Consortium for
Hereditary Breast and Ovarian Cancer and observed mutation prevalences
Families with pathogenic mutation
Families BRCA1/2 BRCA1 BRCA2
Distinct groups of familial BC and
OC history (including proband) N
% of
total n Prev (%) 95% CI (%) n Prev (%) 95% CI (%) n Prev (%) 95% CI (%)
Total 21 401 100.0 5136 24.0 23.4 to 24.6 3398 15.9 15.4 to 16.4 1766 8.3 7.9 to 8.6
≥3 females with BC51+ (no BC<51, no
OC, no mBC)
684 3.2 25 3.7 2.5 to 5.3 9 1.3 0.7 to 2.5 17 2.5 1.6 to 3.9
≥2 females with BC, of these ≥1 with
BC50−(no OC, no mBC)
12 996 60.7 2379 18.3 17.7 to 19.0 1439 11.1 10.5 to 11.6 949 7.3 6.9 to 7.8
Single female with unilateral
BC35−(no further female BC, no OC,
no mBC)
1267 5.9 173 13.7 11.9 to 15.7 116 9.2 7.7 to 10.9 57 4.5 3.5 to 5.8
Single female with bBC50− (no further
female BC, no OC, no mBC)
480 2.2 109 22.7 19.2 to 26.7 73 15.2 12.3 to 18.7 36 7.5 5.5 to 10.2
≥1 females with BC and ≥1 female
with OC (no mBC)
5072 23.7 2111 41.6 40.3 to 43.0 1624 32.0 30.7 to 33.3 500 9.9 9.1 to 10.7
≥2 females with OC (no female BC,
no mBC)
260 1.2 109 41.9 36.1 to 48.0 77 29.6 24.4 to 35.4 34 13.1 9.5 to 17.7
≥1 male with BC and ≥1 females
with BC or OC
642 3.0 230 35.8 32.2 to 39.6 60 9.3 7.3 to 11.8 173 26.9 23.7 to 30.5
bBC, bilateral breast cancer; BC, breast cancer; mBC, male breast cancer; OC, ovarian cancer; Prev, prevalence.
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method. For comparison of mutation frequencies between
groups, the χ2 test was used. p Values <0.05 were considered
significant.
RESULTS
Basic characteristics of the study population are summarised in
table 1. Of 21 401 families, 3398 (15.9%) had a pathogenic
mutation in BRCA1 and 1766 (8.3%) in BRCA2. Of these, 28
families had mutations in both genes, BRCA1 and BRCA2. The
median number of family members documented in each pedi-
gree was 25, regardless of BRCA mutation status. The mean age
at cancer diagnosis was 44.4 years for BC and 49.8 years for
OC in BRCA1-positive families compared with 47.5 and
55.6 years, in BRCA2-positive families, and 50.2 and 51.9 years
in BRCA-negative families. The mean age at diagnosis of mBC
in BRCA1-positive families was 56.9 years, which was younger
than in BRCA2 mutation carriers (60.4 years) and equal to
BRCA1/2-negative families (57.0 years).
The families were classified into seven mutually exclusive
groups of aggregated familial cancer histories (table 2). These
groups cover the inclusion criteria of the GC-HBOC established
in 1996. The overall BRCA1/2 mutation prevalence was 24.0%
(95% CI 23.4% to 24.6%). The highest mutation frequencies
were seen in families with at least two OC (41.9%, 95% CI
36.1% to 48.0%) and families with at least one BC and one OC
(41.6%, 95% CI 40.3% to 43.0%) followed by families with
mBC and at least one additional female with BC or OC (35.8%,
95% CI 32.2% to 39.6%). BRCA1 mutations were more fre-
quent in families with OC, whereas BRCA2 mutations were
more frequent in families with mBC. The largest group com-
prises families with at least two cases of BC, at least one that
was diagnosed before the age of 51 (n=12.996, 60.7% of all
families). The lowest mutation frequencies (3.7%, 95% CI 2.5%
to 5.3%) were observed in families with three or more cases of
postmenopausal BC, but no occurrence of premenopausal BC,
OC or male BC.
To characterise mutation frequencies in more detail, the famil-
ial cancer histories were further refined. Table 3 shows the
mutation prevalences in families, in which exclusively female
BC was present (72.1% of all families). Group 1a comprises
families with exclusive occurrence of unilateral cases of BC
(53.1% of all families), whereas groups 1b (14.6%) and 1c
Table 3 BRCA mutation prevalence in families with female breast cancer only
Families with pathogenic mutation
Familial
cancer history (including proband) Families BRCA1/2 BRCA1 BRCA2
Group BC50− BC51+ N
% of
total n Prev (%) 95% CI (%) n Prev (%) 95% CI (%) n Prev (%) 95% CI (%)
Group 1a:
female unilateral BC
(no bBC, OC, mBC)
0 ≥3 522 2.4 20 3.8 2.5 to 5.8 6 1.1 0.5 to 2.5 15 2.9 1.7 to 4.7
1* 0 1267 5.9 173 13.7 11.9 to 15.7 116 9.2 7.7 to 10.9 57 4.5 3.5 to 5.8
1 1 2577 12.0 227 8.8 7.8 to 10.0 118 4.6 3.8 to 5.5 109 4.2 3.5 to 5.1
1 2 1239 5.8 102 8.2 6.8 to 9.9 54 4.4 3.4 to 5.6 48 3.9 2.9 to 5.1
1 ≥3 579 2.7 43 7.4 5.6 to 9.9 14 2.4 1.4 to 4.0 29 5.0 3.5 to 7.1
2 0 1725 8.1 302 17.5 15.8 to 19.4 187 10.8 9.5 to 12.4 116 6.7 5.6 to 8.0
2 1 1256 5.9 204 16.2 14.3 to 18.4 99 7.9 6.5 to 9.5 105 8.4 7.0 to 10.0
2 2 477 2.2 76 15.9 12.9 to 19.5 33 6.9 5.0 to 9.6 43 9.0 6.8 to 11.9
2 ≥3 239 1.1 41 17.2 12.9 to 22.4 15 6.3 3.8 to 10.1 26 10.9 7.5 to 15.5
≥3 0 739 3.5 225 30.4 27.2 to 33.9 143 19.4 16.7 to 22.4 82 11.1 9.0 to 13.6
≥3 1 462 2.2 127 27.5 23.6 to 31.7 83 18.0 14.7 to 21.7 45 9.7 7.4 to 12.8
≥3 2 177 0.8 50 28.2 22.1 to 35.3 33 18.6 13.6 to 25.0 17 9.6 6.1 to 14.8
≥3 ≥3 103 0.5 25 24.3 17.0 to 33.4 13 12.6 7.5 to 20.4 12 11.7 6.8 to 19.3





1 0 480 2.2 109 22.7 19.2 to 26.7 73 15.2 12.3 to 18.7 36 7.5 5.5 to 10.2
1 1 482 2.3 101 21.0 17.6 to 24.8 69 14.3 11.5 to 17.7 32 6.6 4.7 to 9.2
1 2 204 1.0 41 20.1 15.2 to 26.1 28 13.7 9.7 to 19.1 13 6.4 3.8 to 10.6
1 ≥3 99 0.5 14 14.1 8.6 to 22.3 10 10.1 5.6 to 17.6 4 4.0 1.6 to 9.9
2 0 588 2.7 190 32.3 28.7 to 36.2 140 23.8 20.5 to 27.4 52 8.8 6.8 to 11.4
2 1 348 1.6 109 31.3 26.7 to 36.4 76 21.8 17.8 to 26.5 34 9.8 7.1 to 13.3
2 2 131 0.6 40 30.5 23.3 to 38.9 26 19.8 13.9 to 27.5 14 10.7 6.5 to 17.1
2 ≥3 55 0.3 14 25.5 15.8 to 38.3 9 16.4 8.9 to 28.3 5 9.1 3.9 to 19.6
≥3 0 361 1.7 183 50.7 45.6 to 55.8 135 37.4 32.6 to 42.5 49 13.6 10.4 to 17.5
≥3 1 222 1.0 96 43.2 36.9 to 49.8 72 32.4 26.6 to 38.8 27 12.2 8.5 to 17.1
≥3 2 95 0.4 44 46.3 36.6 to 56.3 26 27.4 19.4 to 37.1 18 18.9 12.3 to 28.0
≥3 ≥3 64 0.3 22 34.4 23.9 to 46.6 13 20.3 12.3 to 31.7 9 14.1 7.6 to 24.6




(no bBC50−, OC, mBC)
0 ≥3 162 0.8 5 3.1 1.3 to 7.0 3 1.9 0.6 to 5.3 2 1.2 0.3 to 4.4
1 1 197 0.9 19 9.6 6.3 to 14.6 3 1.5 0.5 to 4.4 16 8.1 5.1 to 12.8
1 2 175 0.8 14 8.0 4.8 to 13.0 4 2.3 0.9 to 5.7 10 5.7 3.1 to 10.2
1 ≥3 132 0.6 14 10.6 6.4 to 17.0 4 3.0 1.2 to 7.5 10 7.6 4.2 to 13.4
2 1 75 0.4 13 17.3 10.4 to 27.4 7 9.3 4.6 to 18.0 6 8.0 3.7 to 16.4
2 2 69 0.3 9 13.0 7.0 to 23.0 7 10.1 5.0 to 19.5 2 2.9 0.8 to 10.0
2 ≥3 62 0.3 11 17.7 10.2 to 29.0 3 4.8 1.7 to 13.3 8 12.9 6.7 to 23.4
≥3 1 24 0.1 10 41.7 24.5 to 61.2 7 29.2 14.9 to 49.2 3 12.5 4.3 to 31.0
≥3 2 12 0.1 6 50.0 25.4 to 74.6 2 16.7 4.7 to 44.8 4 33.3 13.8 to 60.9
≥3 ≥3 28 0.1 7 25.0 12.7 to 43.4 6 21.4 10.2 to 39.5 1 3.6 0.6 to 17.7
Total 936 4.4 108 11.5 9.6 to 13.7 46 4.9 3.7 to 6.5 62 6.6 5.2 to 8.4
*≤35 years.
bBC, bilateral breast cancer; BC, breast cancer; mBC, male breast cancer; OC, ovarian cancer; Prev, prevalence.
Kast K, et al. J Med Genet 2016;53:465–471. doi:10.1136/jmedgenet-2015-103672 467
Cancer genetics
 on 16 A








enet: first published as 10.1136/jm





(4.4%) include also cases of premenopausal and postmenopausal
bilateral BC, respectively. These groups were further stratified by
the number of women with premenopausal and postmenopausal
BC. The highest mutation frequency was seen in families with at
least three females with premenopausal BC, at least one of
which was bilateral (50.7%, 95% CI 45.6% to 55.8%).
Mutations were detected significantly more frequent in families
with a single case of premenopausal bilateral BC than in families
with two different women with premenopausal BC (22.7%,
95% CI 19.2% to 26.7% vs 17.5%, 95% CI 15.8% to 19.4%,
p=0.012). In families with a single case of very early BC before
the age of 36, mutations were found in 13.7% (95% CI 11.9%
to 15.7%). In all subgroups, the occurrence of additional cases
of postmenopausal BC did not considerably change mutation
frequencies. In contrast, additional cases of premenopausal BC
increased the mutation frequencies considerably.
Table 4 lists families with OC only (group 2a, 1.2% of all
families), families with BC and OC (group 2b, 23.7%) and fam-
ilies with occurrence of mBC (group 3, 3.0%). In families with
one case of BC and one case of OC, mutation frequencies were
considerably higher when the BC case was premenopausal
(31.5% 95% CI 28.0% to 35.2% vs 19.2%, 95% CI 15.3% to
23.8%). Double primary premenopausal BC and OC in one
individual was associated with a much higher mutation preva-
lence than the occurrence of premenopausal BC and OC in two
different women (49.0%, 95% CI 41.0% to 57.0% vs 31.5%,
95% CI 28.0% to 35.2, p<0.001). However, there was no sig-
nificant difference in mutation prevalence between double
primary BC and OC (BCOC) and occurrence of BC and OC in
two different women (BC/OC) when the BC was postmenopau-
sal instead of premenopausal (20.3%, 95% CI 14.1% to 28.5%
vs 19.2%, 95% CI 15.3% to 23.8, p=0.788).
In families with mBC (table 4, group 3) and an additional
case of female BC, no significant difference in mutation frequen-
cies could be detected depending on menopausal status of the
BC (16.5%, 95% CI 10.4% to 25.1% vs 23.2%, 95% CI
16.0% to 32.5%, p=0.284). In families with mBC and add-
itional cases of OC, mutation frequencies for BRCA1 and
BRCA2 mutations were similar in contrast to families without
additional OC cases.
DISCUSSION
Based on a large sample of 21 401 families, the present study
provides a detailed characterisation of BRCA1/2 mutation preva-
lences for defined patterns of familial BC and OC. The under-
lying data were collected over a period of almost 20 years
(1996–2015) in a standardised way within a German multicen-
tre consortium of interdisciplinary university centres specialised
in providing healthcare for families with HBOC. All families
suspected of having HBOC were selected for genetic testing
according to a set of defined clinical criteria that were compul-
sory for all participating centres.
The German HBOC consortium has defined inclusion criteria
for BRCA1/2 testing based on at least three generation pedigree
analysis.6 Currently, GC-HBOC offers genetic testing to index
patients if the expected BRCA mutation probability is ≥10%
based on the individual family cancer history. In our study, the
overall mutation prevalence was 24.0%. The decision threshold
of 10% is exceeded in almost all subgroups of HBOC families
including mBC. However, families with exclusive occurrence of
three or more postmenopausal BC cases (3.2% of all families)
were below the 10% threshold with a mutation of prevalence of
only 3.7%. The latter finding is in line with the study of Frank
et al,11 who reported a prevalence of 3.9%. Interestingly, the
low prevalence observed in our study was independent of
whether bilateral cases were present among the postmenopausal
BCs in the family (3.1%) or not (3.8%). Moreover, mutation
prevalences did not increase with the number of postmenopau-
sal BC cases in the family. On the contrary, in a previous study
we showed that an increasing number of females with BC diag-
nosed at an age of 60 or later was associated with a decreasing
BRCA1/2 mutation frequency.20
In contrast to postmenopausal BC, mutation prevalence
increased considerably with each additional case of premeno-
pausal BC both in families with exclusive occurrence of BC and
in families with BC and OC. This agrees well with the results of
the study of Frank et al.11 In our study, mutation prevalence was
even higher if at least one case of premenopausal BC was bilat-
eral. In contrast, the presence of postmenopausal bilateral BC
did not increase the chance to detect a deleterious mutation.
This observation is in line with a previous study of
Gershoni-Baruch et al,21 who suggested that bBC per se is not
reflective of genetic predisposition, unless associated with early
age of onset. However, other studies came to the conclusion
that mutation frequencies are similar if two cancers (bBC or
BCOC) occurred in one individual compared with two separate
individuals.10 22–24 In our study, mutations were detected signifi-
cantly more often in families with a single case of premenopau-
sal bilateral BC than in families with two independent
premenopausal BC (22.7% vs 17.5%, p=0.012).
In accordance with other studies, the highest mutation rates
were observed in families with BC and OC.4 9 11 12 As observed
in families with exclusive occurrence of BC, mutation preva-
lence was considerably higher if BC cases were premenopausal.
Moreover, mutation prevalence was significantly higher in indi-
viduals with double primaries of ovarian and premenopausal
BC than if these two cancers occurred in different women.
Our study comprised 642 families with mBC. Due to the
inclusion criteria, these families had at least one additional case
of female BC or OC. As described in previous studies, BRCA2
mutations were found more frequently than BRCA1 mutations
in families with mBC but without occurrence of OC. In cases
where additional OC cases were present in these families, a
similar prevalence of mutations was found in BRCA1 and
BRCA2. The additional presence of a premenopausal versus
postmenopausal BC increased the mutation prevalence from
16.5% to 23.2%, although this difference was not significant
due to low sample sizes in these groups.
The present study revealed a mutation prevalence of 13.7%
(9.2%, 95% CI 7.7% to 10.9% for BRCA1 and 4.5%, 95% CI
3.5% to 5.8% for BRCA2) for individuals with early unilateral
BC before the age of 36 years without further cancer cases in
their family. This is in line with results from two other
studies.25 26 However, there is evidence in the literature that the
prevalence of BRCA1 and BRCA2 mutations is high in women
with triple-negative breast cancer (TNBC) and that BRCA1/2
mutations are not restricted to young women or patients with a
positive family history.27 Thus, single cases of TNBC might be
considered in BRCA1/2 genetic testing guidelines with an
extended age of onset that requires further exploration to
confirm a potential cut-off at the age of 60 years as suggested by
the data of Couch et al.27
Comparison of our data to empiric mutation frequencies of
other groups is difficult due to varying inclusion criteria. For
example, in high-risk HBOC families of Czech ancestry an
overall detection rate of 29% was reported compared with
24.0% by us.12 That work was restricted to first-degree and
second-degree relatives in the maternal line and to third-degree
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relatives in the case of paternal transmission. In the work of
Frank et al,11 the overall detection frequency was 15.7% in
non-Ashkenazi individuals, but postmenopausal BC was not
taken into account.
Some limitations have to be mentioned. First, in our study
only aggregated familial cancer histories were correlated with
mutation prevalence, that is, the pedigree size and family struc-
ture was not considered. Mutation prediction algorithms such as
BOADICEA, BRCAPRO or IBIS, which use the pedigree struc-
ture and an underlying genetic model of inheritance, might
have a better predictive performance.28–31 Second, it is known
that BRCA1/2-associated OCs are characterised by a high grade
(G2/3) serous histology.32–34 In our study, we did not restrict
the analysis to OC with specific pathological features since path-
ology information was not available for all OC. Thus, we
cannot exclude that a restriction to this specific type of OC
would have led to larger mutation frequencies.
In summary, we provide a detailed overview on empiric
BRCA1/2 mutation frequencies for at-risk individuals with dif-
ferent familial cancer histories. The number of postmenopausal
BC failed to show a systematic correlation with mutation fre-
quency. Bilateral BC or premenopausal BC and OC in one
affected family member conferred a higher mutation prevalence
than two primaries in separate individuals. Our analysis provides
a simple means to get an overview about expected mutation
probabilities during clinical and genetic counselling before
mutation testing is considered for both counsellors and counse-
lees. Moreover, our results provide guidance for healthcare pro-
fessionals and decision-makers to define consistent clinical
criteria for decision-making to undergo genetic testing for indi-
viduals with suspected HBOC.
Author affiliations
1Department of Gynecology and Obstetrics, University Hospital Carl Gustav Carus,
TU Dresden, Dresden, Germany
2German Cancer Consortium (DKTK) Dresden and German Cancer Research Center
(DKFZ), Heidelberg, Germany
3Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology
(CIO) and Center for Molecular Medicine Cologne (CMMC), Medical Faculty,
University of Cologne and University Hospital Cologne, Cologne, Germany
4Department for Gynecology and Obstetrics, LMU Munich, Munich, Germany
5Department for Gynecology and Obstetrics, Technical University of Munich, Munich,
Germany
6Breast Center, Department of Gynecology, Red Cross Hospital, Munich, Germany
7Institute of Human Genetics, Heidelberg University, Heidelberg, Germany
8Department of Gynecology and Obstetrics, Heidelberg University Hospital,
Heidelberg, Germany
9German Cancer Consortium (DKTK), NCT Heidelberg and German Cancer Research
Center (DKFZ), Heidelberg, Germany
Table 4 BRCA mutation prevalence in families with ovarian cancer (OC) only (group 2a), both breast cancer (BC) and OC (group 2b), and male
breast cancer (mBC) (group 3)
Families with pathogenic mutation







(%) 95% CI (%) n
Prev
(%) 95% CI (%) n
Prev





194 0.9 79 40.7 34.1 to 47.8 50 25.8 20.1 to 32.4 29 14.9 10.6 to 20.6
≥3 OC
(no BC, mBC)
66 0.3 30 45.5 34.0 to 57.4 27 40.9 29.9 to 53.0 5 7.6 3.3 to 16.5
Total 260 1.2 109 41.9 36.1 to 48.0 77 29.6 24.4 to 35.4 34 13.1 9.5 to 17.7





118 0.6 24 20.3 14.1 to 28.5 17 14.4 9.2 to 21.9 7 5.9 2.9 to 11.7
1 BC50−OC
(no mBC)
145 0.7 71 49.0 41.0 to 57.0 56 38.6 31.1 to 46.7 15 10.3 6.4 to 16.4
≥2 BCOC
(no mBC)
11 0.1 7 63.6 35.4 to 84.8 7 63.6 35.4 to 84.8 0 0.0 0.0 to 25.9
≥2 BCOC+≥1
BC/OC (no mBC)
1482 6.9 796 53.7 51.2 to 56.2 641 43.3 40.8 to 45.8 160 10.8 9.3 to 12.5
1 BC51++1 OC
(no mBC, BCOC)
333 1.6 64 19.2 15.3 to 23.8 39 11.7 8.7 to 15.6 26 7.8 5.4 to 11.2
1 BC50−+1 OC
(no mBC, BCOC)
645 3.0 203 31.5 28.0 to 35.2 155 24.0 20.9 to 27.5 48 7.4 5.7 to 9.7
1 BC+≥2 OC
(no mBC, BCOC)
248 1.2 113 45.6 39.5 to 51.8 100 40.3 34.4 to 46.5 13 5.2 3.1 to 8.8
≥2 BC+≥1 OC
(no mBC, BCOC)
2090 9.8 833 39.9 37.8 to 42.0 609 29.1 27.2 to 31.1 231 11.1 9.8 to 12.5
Total 5072 23.7 2111 41.6 40.3 to 43.0 1624 32.0 30.7 to 33.3 500 9.9 9.1 to 10.7
Group 3: mBC 1 mBC+1 BC51+
(no OC)
97 0.5 16 16.5 10.4 to 25.1 3 3.1 1.1 to 8.7 13 13.4 8.0 to 21.6
1 mBC+1 BC50−
(no OC)
99 0.5 23 23.2 16.0 to 32.5 5 5.1 2.2 to 11.3 18 18.2 11.8 to 26.9
1 mBC+≥2 BC
(no OC)
331 1.5 128 38.7 33.6 to 44.0 29 8.8 6.2 to 12.3 100 30.2 25.5 to 35.4
≥2 mBC+≥1 BC
(no OC)
23 0.1 15 65.2 44.9 to 81.2 1 4.3 0.8 to 21.0 15 65.2 44.9 to 81.2
1 mBC+≥1 OC
(no BC)
15 0.1 8 53.3 30.1 to 75.2 4 26.7 10.9 to 52.0 4 26.7 10.9 to 52.0
≥1 mBC+≥1 BC
+≥1 OC
77 0.4 40 51.9 41.0 to 62.7 18 23.4 15.3 to 34.0 23 29.9 20.8 to 40.8
Total 642 3.0 230 35.8 32.2 to 39.6 60 9.3 7.3 to 11.8 173 26.9 23.7 to 30.5
Prev, prevalence.
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